Caesars Entertainment
CZR
$29.94
+0.13%
Caesars Entertainment is a leading casino and resort operator with approximately 50 domestic gaming properties across Las Vegas and regional markets, offering slot machines, table games, hotel accommodations, and a digital sports betting platform. As one of the largest casino operators in the U.S., it holds a distinct competitive position through its iconic brand portfolio including Caesars, Harrah's, and Flamingo, and its dominant presence in both Las Vegas and regional markets. The current investor narrative centers on the proposed $17.6 billion take-private acquisition by Fertitta Entertainment at a 49% premium, which has driven significant stock appreciation and debate about the deal's completion, while the company continues to navigate a heavy debt load and a challenging digital transition.…
CZR
Caesars Entertainment
$29.94
Related headlines
Investment Opinion: Should I buy CZR Today?
Rating: Hold. The thesis is that Caesars is a deep value play with a binary buyout catalyst, but the high leverage and persistent losses make it unsuitable for risk-averse investors. The consensus analyst rating is 'hold' with an average target of $31.93, implying 6.9% upside, which is modest given the risks. Supporting Evidence: The stock trades at a P/S of 0.42x, a 72% discount to the industry average of 1.5x, reflecting its distressed profile. Revenue growth is modest at 2.7% YoY, but gross margins improved to 50.3% in Q1 2026 from 37.3% in Q4 2025. TTM free cash flow is $496 million, providing some cushion, but Q1 2026 FCF was negative. The analyst high target of $41.00 implies 37.3% upside if the buyout succeeds, but the low target of $31.00 offers only 3.8% upside. Risks & Conditions: The biggest risk is buyout failure, which could send the stock to $17.86 (52-week low). A second risk is rising interest rates, which would increase the $569 million quarterly interest expense. A third risk is a recession reducing casino revenue. This Hold would upgrade to Buy if the buyout is definitively approved or if the company achieves sustained GAAP profitability (e.g., two consecutive quarters of positive net income). It would downgrade to Sell if the buyout is officially terminated or if revenue growth turns negative. Valuation Verdict: The stock is undervalued on a P/S basis relative to history and peers, but the discount is justified by its high leverage and lack of profitability. The buyout premium provides a floor, but without it, the stock is fairly valued at best.
Sign up to view all
CZR 12-Month Price Forecast
The 12-month outlook for Caesars is highly dependent on the Fertitta buyout outcome. In the base case (45% probability), the stock trades near $31.93, offering modest upside. The bull case (30%) sees the deal closing at $41.00, while the bear case (25%) could see a drop to $17.86 if the deal fails. The neutral stance reflects the balanced risk/reward: the deep value P/S provides a floor, but the lack of profitability and high leverage cap upside without the buyout. Key developments to watch include regulatory decisions on the buyout and Q2 2026 earnings. An upgrade to bullish would require definitive deal approval; a downgrade to bearish would follow deal termination.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Caesars Entertainment's 12-month outlook, with a consensus price target around $31.27 and implied upside of +4.4% versus the current price.
Average Target
$31.27
0 analysts
Implied Upside
+4.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$31 - $35
Analyst target range
The stock is covered by 15 analysts, with a consensus recommendation of 'hold' (mean rating 2.53 on a 1-5 scale where 1 is strong buy). The average target price is $31.93, implying a modest 6.9% upside from the current price of $29.86. The distribution shows a neutral leaning, with recent downgrades from multiple firms (Barclays, Stifel, Deutsche Bank, Macquarie, JP Morgan, Susquehanna, Truist) in late May/June 2026, reflecting caution around the buyout's execution risk. The target range spans from $31.00 (low) to $41.00 (high), with the high target implying 37.3% upside and likely assuming successful completion of the Fertitta buyout at the announced premium. The low target of $31.00 is only 3.8% above the current price, suggesting limited downside risk but also limited upside if the deal fails. The wide spread of $10.00 (32% of the average target) signals high uncertainty, consistent with the binary outcome of the buyout. The recent wave of downgrades from buy to hold/neutral indicates analysts are tempering expectations, possibly due to concerns about regulatory approval or financing.
Drowning in data?
Find the real signal!
Bulls vs Bears: CZR Investment Factors
Caesars Entertainment presents a binary investment case centered on the proposed $17.6 billion take-private acquisition by Fertitta Entertainment. The bull case is driven by the 49% premium offer, deep value valuation (P/S 0.42x vs. industry 1.5x), and improving gross margins. The bear case highlights persistent GAAP losses, extreme leverage (debt-to-equity 7.52), and significant execution risk for the buyout. Currently, the bull side has stronger evidence due to the tangible premium and deep value support, but the bear case is equally compelling given the financial fragility. The single most important tension is whether the Fertitta buyout closes: if it does, shareholders could see a 37%+ gain to the high target; if it fails, the stock could retest its 52-week low of $17.86, a 40% downside. The recent wave of analyst downgrades suggests the market is pricing in a lower probability of deal completion, making this a high-risk, high-reward situation.
Bullish
- 49% Buyout Premium Offers Significant Upside: Fertitta Entertainment's proposed $17.6 billion take-private deal at a 49% premium to the pre-announcement price provides a clear upside catalyst. The high target of $41.00 implies 37.3% upside from the current $29.86, reflecting strong deal-related optimism.
- Revenue Growth Stabilizing Around 2.7% YoY: Q1 2026 revenue of $2.87 billion grew 2.7% year-over-year, following a multi-quarter trend of $2.87–$2.92 billion. This consistent top-line performance supports a stable operational base, crucial for servicing $7.5 billion in debt.
- Gross Margin Improvement to 50.3%: Gross margin surged to 50.3% in Q1 2026 from 37.3% in Q4 2025, indicating better cost control or mix shift. This improvement, if sustained, could accelerate the path to GAAP profitability.
- Deep Value P/S Ratio Near Historical Lows: The trailing P/S ratio of 0.42x is at the bottom of its five-year range of 1.9x–8.9x and well below the industry average of 1.5x. This deep discount suggests limited downside if the buyout fails, as the market already prices in significant distress.
Bearish
- Persistent GAAP Losses and Negative EPS: Q1 2026 net income was -$98 million (EPS -$0.48), and TTM net income remains negative at -$98 million. High interest expense of $569 million per quarter continues to weigh on profitability, with net margin at -3.4%.
- Extreme Leverage with Debt-to-Equity of 7.52: Total debt of $7.5 billion and a debt-to-equity ratio of 7.52 indicate a highly leveraged balance sheet. The current ratio of 0.80 suggests liquidity pressure, and free cash flow was -$6 million in Q1 2026.
- Buyout Execution Risk and Regulatory Hurdles: The Fertitta buyout faces regulatory approvals and financing risks. Recent downgrades from multiple analysts (Barclays, Stifel, Deutsche Bank, etc.) reflect skepticism about deal completion, with the stock trading below the implied deal value.
- Negative ROE of -14.3% Reflects Value Destruction: Return on equity is deeply negative at -14.3%, indicating the company is destroying shareholder value. Combined with negative EPS, this makes the stock unattractive on a fundamental basis without the buyout.
CZR Technical Analysis
The stock is in a strong recovery uptrend, with the price up 22.6% over the past six months and 26.7% year-to-date, though it remains 1.6% lower over the past year. Currently trading at $29.86, the stock sits at 96.4% of its 52-week range ($17.86–$30.96), indicating it is near the highs and reflecting strong momentum following the buyout announcement. The 1-year decline of 1.6% contrasts with the sharp recovery, suggesting the stock has reversed its prior downtrend. Short-term momentum is accelerating: the 1-month price change is +2.2% and the 3-month change is +9.7%, both outpacing the S&P 500's respective gains of 0.3% and 4.7%. This divergence from the negative 1-year trend signals a potential trend reversal driven by the buyout catalyst, rather than a temporary pullback. The stock's beta of 1.76 indicates it is 76% more volatile than the market, amplifying both upside and downside moves. The 52-week low of $17.86 provides strong support, while the 52-week high of $30.96 is the immediate resistance. A breakout above $30.96 would signal continued upside toward analyst targets, while a breakdown below $17.86 would negate the recovery and suggest renewed weakness.
Beta
1.76
1.76x market volatility
Max Drawdown
-42.4%
Largest decline past year
52-Week Range
$18-$31
Price range past year
Annual Return
+4.5%
Cumulative gain past year
| Period | CZR Return | S&P 500 |
|---|---|---|
| 1m | +1.1% | +1.4% |
| 3m | +6.5% | +3.3% |
| 6m | +28.2% | +6.3% |
| 1y | +4.5% | +16.0% |
| ytd | +27.1% | +8.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CZR Fundamental Analysis
Revenue has shown steady growth, with Q1 2026 revenue of $2.87 billion up 2.7% year-over-year, following Q4 2025 revenue of $2.916 billion and Q3 2025 revenue of $2.869 billion. The multi-quarter trend shows revenue stabilizing around $2.87–$2.92 billion, with modest YoY growth. Casino revenue of $1.666 billion (58% of total) is the primary driver, while hotel ($487 million) and food & beverage ($424 million) segments contribute meaningfully. The growth trajectory is modest but consistent, supporting a stable investment case. The company remains unprofitable on a GAAP basis, with Q1 2026 net income of -$98 million and EPS of -$0.48, though this is an improvement from -$250 million in Q4 2025. Gross margin improved to 50.3% in Q1 2026 from 37.3% in Q4 2025, while operating margin was 17.4%. The net margin of -3.4% reflects persistent interest expense ($569 million in Q1 2026) weighing on profitability. The trajectory toward profitability is uneven, with losses narrowing from -$250 million to -$98 million over the past two quarters. The balance sheet shows high leverage, with a debt-to-equity ratio of 7.52 and total debt of $7.5 billion. Free cash flow was -$6 million in Q1 2026, though TTM free cash flow is $496 million. The current ratio of 0.80 indicates liquidity pressure, and the company relies on external financing to fund operations. ROE is negative at -14.3%, reflecting persistent losses and high leverage.
Quarterly Revenue
$2.9B
2026-03
Revenue YoY Growth
+2.7%
YoY Comparison
Gross Margin
50.3%
Latest Quarter
Free Cash Flow
$496000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CZR Overvalued?
Since net income is negative (TTM net income of -$98 million), the P/E ratio is not meaningful, so we use the price-to-sales (P/S) ratio as the primary valuation metric. The trailing P/S ratio is 0.42x, while the forward P/S (based on estimated revenue of $12.29 billion) is approximately 0.40x. The gap between trailing and forward P/S is negligible, suggesting the market expects stable revenue growth. Compared to the industry average P/S of 1.5x (estimated for consumer cyclical/gaming), Caesars trades at a 72% discount, reflecting its high debt load and lack of profitability. This discount may be justified by the company's elevated financial risk and negative earnings, but the buyout premium could narrow the gap. Historically, the stock's P/S ratio has ranged from 1.9x to 8.9x over the past five years. The current P/S of 0.42x is near the bottom of its historical range, indicating deep value territory. This suggests the market is pricing in significant distress or a low probability of the buyout closing, but also presents potential upside if fundamentals improve or the deal completes.
PE
-9.7x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 3x~76x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
9.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Caesars' primary financial risk is its extreme leverage, with a debt-to-equity ratio of 7.52 and total debt of $7.5 billion. Interest expense of $569 million in Q1 2026 consumed a significant portion of operating income ($500 million), leaving no margin for error. The company remains unprofitable on a GAAP basis, with a net loss of -$98 million in Q1 2026 and negative free cash flow of -$6 million in the same quarter. The current ratio of 0.80 indicates liquidity pressure, meaning the company may need to refinance or raise capital to meet short-term obligations. Revenue concentration in Las Vegas (48% of EBITDAR) and regional markets (49%) exposes the company to regional economic downturns and competitive pressures from new casino openings. Market & Competitive Risks: The stock's beta of 1.76 makes it highly sensitive to macro downturns, with potential for amplified losses in a bear market. Valuation compression is a risk if the buyout fails, as the current P/S of 0.42x already reflects deep distress, but could fall further if fundamentals deteriorate. Competitive threats include the rise of digital gambling and sports betting, where Caesars' digital segment has been marginal. Regulatory risks include potential changes in gaming laws or tax rates, particularly in key markets like Nevada and New Jersey. The recent exit of Progeny 3 from Caesars' shareholder base signals institutional concern about the company's debt and digital transition. Worst-Case Scenario: If the Fertitta buyout fails due to regulatory or financing issues, the stock could lose its premium and retest the 52-week low of $17.86, representing a 40% decline from the current price of $29.86. In a severe recession, with declining casino revenue and rising interest costs, the stock could fall further to $15.00 (a 50% loss), as the company may struggle to service its debt. The historical max drawdown of -42.43% suggests that a decline to $17.20 is plausible, consistent with the 52-week low scenario.
FAQ
The primary risk is buyout failure: if the Fertitta deal falls through, the stock could drop 40% to the 52-week low of $17.86. Financial risk is severe: with a debt-to-equity ratio of 7.52 and interest expense of $569 million per quarter, the company is highly leveraged and has negative net income. Competitive risk includes the rise of digital gambling and regional competition, which could pressure margins. Macro risk is elevated due to a beta of 1.76, meaning the stock is 76% more volatile than the market. Additionally, the company has a current ratio of 0.80, indicating potential liquidity issues. The most severe risk is a recession combined with buyout failure, which could push the stock below $17.86.
The 12-month forecast for CZR is binary, centered on the Fertitta buyout. In the bull case (30% probability), the deal closes at $41.00, delivering a 37.3% return. In the base case (45% probability), the stock trades near the analyst average target of $31.93, a 6.9% gain. In the bear case (25% probability), the deal fails and the stock falls to $17.86, a 40% loss. The most likely scenario is the base case, where the stock remains range-bound as the market awaits deal clarity. Key assumptions include stable revenue growth of 2-3% and no major regulatory setbacks. The AI assessment is neutral with medium confidence, reflecting the balanced risk/reward.
CZR appears undervalued on a price-to-sales basis, with a trailing P/S of 0.42x compared to the industry average of 1.5x and its own five-year range of 1.9x–8.9x. This deep discount suggests the market is pricing in significant distress, likely due to the company's high debt (debt-to-equity 7.52) and persistent GAAP losses. On a forward P/E basis, the stock trades at 35.4x estimated 2026 EPS of $0.54, which is elevated but reflects the expectation of a return to profitability. The EV/EBITDA of 9.2x is reasonable for the gaming sector. Overall, the stock is undervalued relative to historical multiples, but the discount is justified by its financial risks. The buyout premium provides a floor, but without it, the stock is fairly valued at best.
CZR is a high-risk, high-reward stock that could be a good buy for speculative investors who believe the Fertitta buyout will close. The analyst average target of $31.93 implies 6.9% upside, but the high target of $41.00 offers 37.3% upside if the deal succeeds. However, the stock trades at a deep value P/S of 0.42x, which provides a margin of safety if the deal fails. The biggest downside risk is a 40% decline to the 52-week low of $17.86 if the buyout collapses. Therefore, CZR is a good buy only for those with a high risk tolerance and a clear thesis on the buyout's completion. Conservative investors should avoid it due to the company's negative earnings and extreme leverage.
CZR is better suited for short-term to medium-term trading, given its binary buyout catalyst and high volatility (beta 1.76). The stock's fate over the next 12 months hinges on the Fertitta deal, making it a tactical play rather than a long-term hold. Long-term investors would face significant risks from the company's high debt load and negative ROE (-14.3%), which suggest value destruction. The stock pays no dividend, so there is no income component. A suggested minimum holding period is 6-12 months, aligned with the expected timeline for buyout resolution. For long-term investment, wait for evidence of sustained profitability and debt reduction.
